Xconomy | Seattle - Business + Technology in the Exponential Economy

Spaltudaq Harnessing Mother Nature’s Wisdom to Make Better Drugs For Infections
Antibodies for HIV, Long Dismissed, Show Signs of Comeback at Seattle’s Theraclone
Dendreon Saga Nears Climax, Gregoire Biotech Fund in Jeopardy, UW’s Biofuel Futurist, & More Seattle-Area Life Sciences News
Seattle’s Theraclone Strikes $18M Deal to Make Flu-Fighting Antibodies with Japanese Company
Finding HIV’s Weak Spot, Scientists at Seattle’s Theraclone and San Diego’s Scripps See Opening for New Vaccine

Spaltudaq Now Theraclone Sciences

Spaltudaq (SPAHL-too-dack), the Seattle-based maker of genetically engineered antibody drugs, has changed its name to Theraclone Sciences. Founder Johnny Stine, a member of the Snohomish tribe, gave the company its original name after a healing ceremony once performed by his ancestors in the Puget Sound region to make sure people don’t die before their time. The new name was chosen to “highlight our ability to clone and express clinically relevant, naturally fully human antibodies for clinical and commercial benefit,” said CEO David Fanning.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: